-
Clinical Trial Underway for New-and-Improved Prostate Cancer Test
Clinical Research News | Researchers at the University of Michigan (U-M) have developed a urine test for prostate cancer known as MyProstateScore 2.0 (MPS2), now a property of spinoff LynxDx, which they expect to significantly improve upon the performance of existing assays by focusing on clinically significant cancers and capturing more biomarkers in a single test.
May 14, 2024
-
How Patient-Mediated Research Can Disrupt Life Sciences
Clinical Research News | The life science industry is changing. There are growing calls for real-world evidence (RWE) and feedback from patients (PROs). Rare diseases are growing in importance, and there is increasing recognition of equity as an ethical and drug-efficacy necessity.
May 10, 2024
-
Functional Precision Medicine Shows Promise for Kids With Tough Cancers
Clinical Research News | A cancer researcher at Florida International University (FIU) has developed a functional precision medicine (FPM) approach to oncology treatment decision-making that combines genomic profiling with drug sensitivity testing on patient-derived tumor cells. Children with relapsed or refractory cancers are among the initial beneficiaries.
May 9, 2024
-
Thermo Fisher on the Rise of Next-Generation Sequencing CDx
Clinical Research News | In oncology, it is well appreciated that time is life. Diagnostics are therefore valuable not just to determine the disease state of patients but how best to treat them, says Jane Li, senior director of oncology, pharma, and CRO partnerships related to clinical sequencing at Thermo Fisher Scientific.
May 7, 2024
-
eConsent In Decentralized Clinical Trials - A Path To Participant Empowerment And Transparency
Clinical Research News | Electronic consent, or eConsent, has emerged as a cornerstone in the decentralized clinical trials (DCTs) landscape. Central to this is the Food and Drug Administration’s (FDA) resounding endorsement of electronic methodologies for obtaining informed consent from clinical trial participants.
May 3, 2024